Aafter raising $ 500 million earlier this year (up to $ 897 million), Ro, which made its name by selling drugs for erectile dysfunction and hair loss to men, announced this month which would acquire the Women Fertility brand, focused on women, for a total of $ 225 million. .
For some observers, Ro’s acquisition of Modern Fertility follows a well-established pattern: Men-founded companies may find it easier to raise capital, even very early in their history, while companies focused on women-founded could struggle to scrape a rounded seed or get more funding. Ro and competitor Hims, for example, were founded by men with a focus on men’s health and raised millions during their first two years with this emphasis, before adding specific health offerings for women.
Unlock this article by subscribing to STAT + and enjoy your first 30 days for free.
STAT + is STAT’s premium subscription service for coverage and analysis in biotechnology, pharmaceuticals, policy and in-depth life sciences. Our award-winning team covers news on Wall Street, policy developments in Washington, early scientific advances, and the results of clinical trials and outages in healthcare in Silicon Valley and beyond.
What does it include?
- Daily reports and analyzes
- The industry’s most comprehensive coverage of a team of powerful reporters
- Newsletters for subscribers only
- Daily newsletters to keep you up to date with the most important industry news of the day
- STAT + conversations
- Weekly opportunities to interact with our journalists and leading industry experts in live video conversations
- Industry-exclusive events
- Premium access to network events for subscribers only nationwide
- The best reporters in the industry
- The most reliable and well-connected newsroom in the healthcare industry
- And much more
- Exclusive interviews with industry leaders, profiles and premium tools, such as our CRISPR Trackr.